An interventional study of Decreased Salt High Potassium Tool (DSHP Tool) in Hypertension, sponsored by Sun Jingfeng. Recruiting at 1 site in Singapore. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-04-30.
Sponsored by Sun Jingfeng · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 56 studies in Hypertension with a site in Singapore — 16 open to participants now, 20 under way, 3 of them phase 3. Hypertension · Singapore.
Among the 56 studies in Hypertension with a site in Singapore, this one is the 21st largest by planned enrollment of the 44 interventional ones that give a count, is one of 3 that started in 2026, is one of 24 with no phase, reaches primary completion later than 17 of the 19 other live ones, and was the 51st registered.
6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.
Browse Hypertension studies →16 of the 56 studies in Hypertension with a site in Singapore are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Singapore, United States, Japan
Ages 18+
Singapore Institute of Food and Biotechnology Innovation · Sites in Singapore
Ages 50–75 · Healthy volunteers
Boehringer Ingelheim · Sites in Singapore, United States, Argentina and 48 more countries
Ages 18+
Changi General Hospital · Sites in Singapore
Ages 21–70
National University of Singapore · Sites in Singapore
Ages 40–64
A study can be open while its sites in Singapore have not opened yet or have stopped. Only those recruiting at a site in Singapore →
Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.
This study: 21 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
56 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 6 · Phase 3 10 · Phase 4 3
First in 2004; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 190 is above the median of 100 across 4,585 interventional studies indexed under Hypertension.
Median enrollment 170 across the 44 interventional studies, 200 across the 9 observational. Of the 25 that completed or were terminated, 7 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 56 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Sun Jingfeng as lead sponsor.
Sun Jingfeng has 1 study filed under Hypertension — fewer than ten, so there is no comparison to draw.
3 of the studies in Hypertension with a site in Singapore that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03683186Phase 3United TherapeuticsA Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2026-12 |
| NCT07922837National University Polyclinics, SingaporeDigital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals | 2026-12 |
| NCT06890169Changi General HospitalOneSTOP (One-Stop Telehealth Obesity Program) for Multidisciplinary Weight Management and Related Comorbidities | 2027-02-28 |
Add all 3 to your calendar (.ics) → With an account.
Among the 56 studies in Hypertension with a site in Singapore, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this study is to explore the barriers and facilitators to adopting a reduced dietary salt and increased potassium intake among adults with essential hypertension in Singapore, and to evaluate the feasibility and preliminary effectiveness of a newly developed educational tool-Decreased Salt High Potassium (DSHP) Diet Tool-in reducing dietary sodium intake and increasing potassium intake.
This three-part study will involve adults aged 21 years and above, with a self-reported diagnosis of hypertension for at least six months and/or currently taking antihypertensive medication. Participants will be recruited from two SingHealth Polyclinics (Punggol Polyclinic and Pasir Ris Polyclinic). Healthcare providers (HCPs) working at these clinics who have experience in managing patients with hypertension and in educating patients on reducing dietary sodium intake will also be recruited.
The main questions this study aims to answer are:
Participants in the intervention group will be provided DSHP Diet Tool and Decreased Salt High Potassium patient information leaflet (DSHP PIL). Participants in the control group will receive standard care and a patient information leaflet (DSHP PIL). Researchers will compare participants in the intervention group to the control group to determine whether the DSHP tool is effective in reducing dietary sodium and increasing potassium intake in patients with hypertension.
Hypertension is a major public health concern globally, contributing to cardiovascular disease and premature mortality. According to the World Health Organization (2023), one in three adults worldwide suffers from hypertension. In Singapore, the 2022 National Population Health Survey reported that over 35% of residents aged 18 to 74 years had hypertension, with nearly 65% of those under medical follow-up exhibiting poor blood pressure control. One of the most significant and modifiable risk factors for hypertension is diet-specifically, excessive sodium (salt) intake and insufficient potassium intake.
Excess sodium elevates blood pressure by causing fluid retention and adversely affecting vascular function. Conversely, potassium intake helps regulate blood pressure through mechanisms like promoting sodium excretion and reducing vascular resistance. The benefits of dietary sodium reduction and increasing potassium intake are well-established in both clinical trials and population studies, particularly in individuals with hypertension.
Despite this, Singaporeans continue to consume well above the recommended daily intake for sodium and below the optimal levels for potassium. The average sodium intake is approximately 3,620 mg/day (exceeding the WHO recommendation of 2,000 mg/day), while potassium intake averages 2,500 mg/day (below the recommended 3,510 mg/day). Public health initiatives like the "War on Salt" campaign (launched in 2011) have had limited long-term success in addressing these dietary gaps.
Previous studies in Singapore and neighboring countries have identified significant gaps in knowledge, attitudes, and behaviors related to dietary sodium and potassium. However, there has been limited research focused on practical, context-specific educational interventions aimed at improving dietary behaviors related to salt and potassium intake, especially within the hypertensive population in the primary care setting.
Study Objectives and Hypothesis This study is designed in three parts to systematically develop, refine, and evaluate a novel educational tool-the Decreased Salt High Potassium (DSHP) Diet Tool-for hypertensive patients. The tool aims to support patients in reducing dietary sodium and increasing potassium intake, thereby improving blood pressure control and overall cardiovascular risk profiles.
Primary Hypothesis: A targeted educational tool, developed based on patient and healthcare provider input, will be feasible and effective in supporting reductions in sodium intake and increases in potassium intake among hypertensive patients, leading to improved blood pressure outcomes.
Objectives:
Part 1:
Part 2:
Part 3:
* Conduct a pilot randomized controlled trial (RCT) to evaluate the feasibility, usability, and preliminary effectiveness of the DSHP Diet Tool in real-world clinical settings.
Study Design Overview
The study will be conducted in three distinct but interrelated parts:
Part 1: Qualitative study
Design: Qualitative study using in-depth interviews and/or focus group discussions guided by the Theoretical Domains Framework (TDF). Population: 40 hypertensive patients and 20 healthcare providers from two SingHealth Polyclinics (Punggol and Pasir Ris). Sampling: Purposive sampling to ensure diversity in age, gender, ethnicity in patients Data Collection:
* Audio-recorded, semi-structured interviews will be carried out Data Analysis: Thematic analysis using the TDF as a guiding framework. Coding will be conducted independently by multiple researchers to ensure reliability. Data collection will continue until saturation is achieved.
Part 2: Development and Alpha Testing of DSHP Diet Tool
Design: Mixed-methods developmental study. Tool Development: Content developed using findings from Part 1 and validated through collaboration with dietitians, nurses, content experts, and HCPs. Components include:
Alpha Testing:
Outcome Measures:
Part 3: Pilot Randomized Controlled Trial (RCT) Design: Parallel, two-arm, 1:1 allocation pilot RCT with mixed-method evaluation. Sites: SingHealth Polyclinic - Punggol and SingHealth Polyclinic - Pasir Ris. Sample Size: 80 patients with hypertension (40 per arm), with 25% over-recruitment to account for attrition. Randomization: Using sealed, sequentially numbered opaque envelopes (SNOEs) prepared by an independent researcher. Duration: 24-week intervention period.
Arms:
Assessments (Baseline and 24 weeks):
Qualitative Component: At the end of the RCT, a subset of patients from the intervention group will participate in interviews to provide in-depth feedback on acceptability, usability of the DSHP Tool.
Statistical Methods
Quantitative Analysis:
Qualitative Analysis:
Ethical Considerations and Safety
Expected Impact and Significance
This study aims to address critical gaps in dietary management of hypertension in Singapore by:
Inclusion Criteria for patients:
Exclusion Criteria for patients:
Inclusion criteria for Healthcare providers:
Exclusion criteria for healthcare providers
-nil
Participants in this arm will receive standard hypertension care along with access to the Decreased Salt High Potassium (DSHP) Diet Tool for 24 weeks and DSHP Patient information leaflet. The DSHP Tool is a patient-centered educational resource developed to support sodium reduction and increase potassium intake through practical strategies, goal setting, and food guidance. Participants will also receive the DSHP Patient Information Leaflet (PIL). Patients will be guided on how to use the tool by a study coordinator. Clinical and dietary assessments will be conducted at baseline and at the end of the intervention.
Behavioral: Decreased Salt High Potassium Tool (DSHP Tool)
Participants in this arm will receive standard hypertension care as provided at SingHealth Polyclinics, along with the DSHP Patient Information Leaflet (PIL). The PIL provides written guidance on reducing sodium and increasing potassium intake. No access to the DSHP Tool will be provided in this arm. Participants will undergo the same clinical and dietary assessments as the intervention group at baseline and after 24 weeks.
Participants in this arm will receive standard hypertension care and the Decreased Salt High Potassium (DSHP)Tool for 24 weeks. The DSHP Tool is an educational resource which includes a sodium intake calculator and tracker, potassium-rich food lists, risk matrix visuals, goal-setting modules tailored to the Singaporean diet. Participants will also receive the DSHP Patient Information Leaflet (PIL) .
24 hour Urinary Sodium level
24 hour urinary sodium level will be assessed at baseline and at the end of the intervention
Time frame: At baseline and at the end of the intervention (24 weeks)
24 hour urinary potassium level
24 hour urinary potassium level will be measured at baseline and at the end of intervention (24 weeks)
Time frame: at baseline and at the end of intervention (24 weeks)
Blood pressure
Blood pressure will be assessed at baseline and at the end of the intervention (24 weeks)
Time frame: at baseline and at the end of intervention (24 weeks)
Body mass index
Body mass index will be measured at baseline and at the end of 24 weeks
Time frame: at baseline and at the end of 24 weeks
Salt literacy scale
Salt literacy scale will be measured at baseline and at the end of intervention (24 weeks). Changes in salt literacy will be assessed using a validated Health Literacy Scale for Low Salt Consumption, which measures participants' knowledge, attitudes, and behaviors related to salt intake. The salt literacy scale has a possible score ranging from 0 to 98, with a higher score indicating higher health literacy related to low salt intake.
Time frame: At baseline and at the end of intervention (24 weeks)
DASH score
DASH score will be measured at baseline and at the end of intervention (24 weeks). Adherence to the DASH (Dietary Approaches to Stop Hypertension) diet will be evaluated using the DASH score questionnaire, reflecting overall dietary behavior in relation to sodium and potassium intake. Minimum Score: 0, Maximum Score: 63 , with higher score indicating better adherence to the DASH diet
Time frame: at baseline and at the end of intervention (24 weeks)
Plan to share: No — Individual participant data (IPD) will not be shared due to concerns about maintaining participant confidentiality and data privacy. As the study involves sensitive health information and is conducted in a clinical setting, data sharing could increase the risk of re-identification despite de-identification measures. Additionally, participants were not consented for public data sharing at the time of enrollment.
Start is estimated for Apr 2026; primary completion for Jul 2030, 51 months later.
Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 51 months is above that.
Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.